Secondary Stock OfferingsBy The Online Investor Staff, updated Thu., Feb. 22, 9:39 AM
|This Slide: #3 of 25|
Slide #3. Ascendis Pharma A/S — Secondary Offering
Ascendis Pharma A/S (NASDAQ:ASND)
Secondary Offering Details:
Ascendis Pharma A/S (Nasdaq:ASND), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $150,000,000 of American Depositary Shares ("ADSs"), each of which represents one ordinary share of Ascendis. All of the ADSs are being offered by Ascendis. In addition, Ascendis expects to grant the underwriters a 30-day option to purchase up to an additional $22,500,000 of ADSs at the public offering price, less the underwriting commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Ascendis Pharma is a biotechnology pharmaceutical company based in Denmark. Co. is engaged in developing differentiated prodrug versions of high-value drugs. Co.'s proprietary TransCon technology is used to generate product candidates that are improved versions of existing drugs for use in the treatment of pediatric growth hormone deficiency, adult growth hormone deficiency, pulmonary arterial hypertension, diabetes and Ophthalmology. Co. creates long acting prodrugs of proteins, peptides and small molecules, suitable for either local or systemic treatment. Co. maintains offices in Palo Alto, California and research and clinical development sites in Heidelberg, Germany and Copenhagen.
Open the ASND Page at The Online Investor »
Strong Buy (3.60 out of 4)
(ranked higher than approx. 72% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite